Lokelma (Sodium Zirconium Cyclosilicate) Patent Expiration, LOE Window & CMS Spending

Lokelma (Sodium Zirconium Cyclosilicate) by AstraZeneca: FDA Orange Book core substance LOE 2035-10-14, 1 AB generics, $279.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstraZeneca
FDA Application & PathwayN207078 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2035-10-14
Last Listed Patent or Exclusivity Date2035-10-14
Orange Book Patents (*PED Extensions)14 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$279.1M
2024 Medicare Part D Spend$239.0M
2024 Medicaid Spend$40.1M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.